Eptacog beta for bleeding in Glanzmann's thrombasthenia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial is testing a medication called eptacog beta (a clotting factor) to see if it helps control or prevent severe bleeding episodes in people with Glanzmann's thrombasthenia, a rare inherited bleeding disorder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Glanzmann's thrombasthenia (a rare bleeding disorder passed down in families).
- You must have a history of severe bleeding episodes.
- Your liver and kidneys must be working well enough.
- You cannot have a low platelet count (under 100,000).
- You must not have had a blood clot in the last 2 years.
- You cannot be taking aspirin, NSAIDs (like ibuprofen), blood thinners, or certain natural remedies while in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for adults with Glanzmann thrombasthenia, a rare bleeding disorder. It aims to learn more about the condition and how to care for patients.
This study looks at genes and blood function in people with inherited (passed-down) problems with platelets, white blood cells, or blood clotting. It may help improve understanding of the cause of these conditions and how they work in the body.
This study uses special video imaging to try to predict when bleeding may happen in certain inherited bleeding disorders. It may help doctors better anticipate bleeding and guide safer care.
This trial is studying children with Glanzmann thrombasthenia who are currently having bleeding episodes. It aims to understand the pattern of bleeding and how the condition shows up in children.
This trial tests a new medicine, bometase alfa, to stop bleeding in people with a rare bleeding disorder called acquired hemophilia A. The goal is to control active bleeding episodes safely.
This trial tests whether a medication called recombinant von Willebrand factor (vWF) can help control major bleeding in adults who are on life support with ECMO. If you are on ECMO and have a serious bleed, this treatment might help stop the bleeding.
Hear when a new Glanzmann Thrombasthenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.